
Breakthrough for MALE birth control pill: Experimental hormone–free tablet passes its first safety test in men
But that could soon change – as an experimental pill for men that works by blocking sperm production has just passed its first safety test in humans.
The hormone–free contraceptive tablet, called YCT–529, has already been found to prevent 99 per cent of pregnancies during experiments in mice.
It works by blocking access to vitamin A in the testes, preventing sperm production without affecting testosterone levels – meaning libido is not impacted.
The male pill, which experts hope will be available this decade, is the only one currently being tested in humans.
For the latest trial, researchers recruited 16 men who were put on different doses of the pill across several days.
Instead of testing how effective it was in humans – all of the men had undergone vasectomies – the aim was to discover if there were any side–effects.
Analysis revealed there were no concerning changes in heart rate, hormone function, inflammation, mood or sexual function.
Next, the team will test the pill in larger trials that will look at how effective it is in preventing sperm production in humans.
The results of the safety trial, published in the journal Communications Medicine, are a critical first step toward getting the pill approved, experts said.
'We really need more reversible contraceptive methods for men,' Dr Stephanie Page, an endocrinologist at the University of Washington School of Medicine and who wasn't involved in the study, told Scientific American.
Currently, the other male birth control options are vasectomies – a surgical procedure that involves cutting and sealing the tubes that carry sperm from the testicles – or condoms.
Vasectomies, also known as 'the snip', can be reversed but the success rate of reversal procedures vary widely.
Earlier tests in male primates also found the drug lowered sperm counts within just two weeks.
Crucially, both mice and non–human primates fully regained fertility after stopping the drug and no side effects were detected in either species.
Mice regained fertility within six weeks, while non–human primates fully recovered their sperm count in 10 to 15 weeks.
How does it work?
Researchers have understood for decades that vitamin A is essential for male fertility.
YCT–529 is a retinoic acid receptor–alpha (RAR–a) inhibitor that prevents production of sperm cells in the testes as well as their release.
It does this by blocking RAR–alpha – one of three nuclear receptors that bind retinoic acid, a form of vitamin A.
YCT–529 is being worked on as part of a collaboration between University of Minnesota College of Pharmacy, Columbia University in New York and San Francisco–based firm YourChoice Therapeutics.
'A safe and effective male pill will provide more options to couples for birth control,' Gunda Georg, chemist and pharmacist at the University of Minnesota, said earlier this year.
'It will allow a more equitable sharing of responsibility for family planning and provide reproductive autonomy for men.'
Both the animal studies and the human trial results suggest that the approved pill would likely be taken once a day, but further trials will confirm that dosing.
'The positive results from this first clinical trial laid the groundwork for a second trial, where men receive YCT–529 for 28 days and 90 days, to study safety and changes in sperm parameters,' the study authors wrote in their paper, published in the journal Communications Medicine.
Currently, around a quarter of women who use contraception take an oral birth control pill, but there are no equivalent methods available for men.
If the male pill proves to be as effective in humans as it is in mice, it would be on a par with the female birth control medication.
Lead author and YourChoice Therapeutics' Chief Science Officer Nadja Mannowetz said: 'A peer–reviewed publication for our first–in–human study reinforces YCT–529's strong safety profile.
'It also shows "the Pill for men" had no effect on sexual desire or mood.'
Nearly half of all pregnancies globally are unintended, suggesting an urgent need for more male contraceptive options.
There is also high demand for new methods.
A recent study showed men are very interested in using new male contraceptive options and women are confident they'll take them correctly.
'Studies and surveys continue to show that men want to share the burden of pregnancy prevention with their partners,' Akash Bakshi, CEO of YourChoice Therapeutics, said.
'But they have just one non–permanent contraceptive option—condoms—and it's 170 years old. Innovation is long overdue.
'Data show men favour an oral contraceptive and one that's hormone–free, positioning YCT–529 as potentially transformative for a healthcare segment that's been stagnant for more than a century and a half.'
Women have several birth control options available including short–term rapid methods like birth control pills and patches and a contraceptive cap or diaphragm.
They also have long–term options such as implants, which produce hormones that stop the release of an egg.
Some opt for an intrauterine device – a T–shaped device placed into the uterus to prevent an egg from implanting.
The birth control pill or patches are about 93 per cent effective at preventing pregnancies.
However long–term devices like the intrauterine device are more than 99 per cent effective.
There have been few changes in male contraception compared with the range of options available to women.
Although there's ongoing research into a male contraceptive pill, there is not one available yet.
At the moment, the 2 contraceptive methods available to men are:
Condoms – a barrier form of contraception that stops sperm from reaching and fertilizing an egg
Vasectomy – a minor, usually permanent, surgical procedure that stops sperm from reaching the semen ejaculated from the penis
The withdrawal method of taking your penis out of your partner's vagina before ejaculating is not a method of contraception.
This is because sperm can be released before ejaculation and cause pregnancy.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Guardian
3 minutes ago
- The Guardian
Top medical body concerned over RFK Jr's reported plans to cut preventive health panel
A top US medical body has expressed 'deep concern' to Robert F Kennedy Jr over news reports that the health secretary plans to overhaul a panel that determines which preventive health measures including cancer screenings should be covered by insurance companies. The letter from the the American Medical Association comes after the Wall Street Journal reported on Friday that Kennedy plans to overhaul the 40-year old US Preventive Services Task Force because he regards them as too 'woke', according to sources familiar with the matter. During his second term, Donald Trump has frequently raged against organizations and government departments that he considers too liberal – often without any evidence. The US president, and his cabinet members such as Kennedy, have also overseen huge cuts and job losses across the US government. The taskforce is made up of a 16-member panel appointed by health and human services secretaries to serve four-year terms. In addition to cancer screenings, the taskforce issues recommendations for a variety of other screenings including osteoporosis, intimate partner violence, HIV prevention, as well as depression in children. Writing in its letter to Kennedy on Sunday, the AMA defended the panel, saying: 'As you know, USPSTF plays a critical, non-partisan role in guiding physicians' efforts to prevent disease and improve the health of patients by helping to ensure access to evidence-based clinical preventive services.' 'As such, we urge you to retain the previously appointed members of the USPSTF and commit to the long-standing process of regular meetings to ensure their important work can be continued without disruption,' it added. Citing Kennedy's own slogan of 'Making America healthy again,' the AMA went on to say: 'USPSTF members have been selected through an open, public nomination process and are nationally recognized experts in primary care, prevention and evidence-based medicine. They serve on a volunteer basis, dedicating their time to help reduce disease and improve the health of all Americans – a mission well-aligned with the Make America Healthy Again initiative.' According to the Affordable Care Act, public and private insurance companies must cover any services recommended by the Preventive Services Task Force without cost sharing. In a statement to MedPage Today, Department of Health and Human Services spokesperson Andrew Nixon did not confirm the reports, instead saying: 'No final decision has been made on how the USPSTF can better support HHS' mandate to Make America Healthy Again.' Reports of Kennedy's alleged decision to overhaul the taskforce come after the American Conservative published an essay earlier this month that described the taskforce as advocating for 'leftwing ideological orthodoxy'. It went on to accuse the panel of being 'packed with Biden administration appointees devoted to the ideological capture of medicine', warning that the 'continued occupation of an important advisory body in HHS – one that has the capacity to force private health insurers to cover services and procedures – by leftwing activists would be a grave oversight by the Trump administration'. In response to the essay, 104 health organizations, including the American Medical Association, issued a separate letter to multiple congressional health committees in which they urged the committees to 'protect the integrity' of the taskforce. 'The loss of trustworthiness in the rigorous and nonpartisan work of the Task Force would devastate patients, hospital systems, and payers as misinformation creates barriers to accessing lifesaving and cost effective care,' the organizations said. In June, Kennedy removed all 17 members of a US Centers for Disease Control and Prevention panel of vaccine experts. Writing in a Wall Street Journal op-ed, he accused the committee of having too many conflicts of interest. Kennedy's decision to overhaul the immunization panel was met with widespread criticism from health experts, with the American Public Health Association executive director Georges Benjamin calling the ouster 'a coup'. 'It's not how democracies work. It's not good for the health of the nation,' Benjamin said.


The Independent
2 hours ago
- The Independent
‘Fantastic Four: First Steps' scores Marvel's first $100 million box office opening of 2025
Marvel's first family has finally found box office gold. 'The Fantastic Four: First Steps,' the first film about the superheroes made under the guidance of Kevin Feige and the Walt Disney Co., earned $118 million in its first weekend in 4,125 North American theaters, according to studio estimates Sunday. That makes it the fourth biggest opening of the year, behind 'A Minecraft Movie,' 'Lilo & Stitch' and 'Superman,' and the biggest Marvel opening since 'Deadpool & Wolverine' grossed $211 million out of the gate last summer. Internationally, 'Fantastic Four' made $100 million from 52 territories, adding up to a $218 million worldwide debut. The numbers were within the range the studio was expecting. The film arrived in the wake of another big superhero reboot, James Gunn's 'Superman,' which opened three weekends ago and has already crossed $500 million globally. That film, from the other main player in comic book films, DC Studios, took second place with $24.9 million domestically. 'First Steps' is the latest attempt at bringing the superhuman family to the big screen, following lackluster performances for other versions. The film, based on the original Marvel comics, is set during the 1960s in a retro-futuristic world led by the Fantastic Four, a family of astronauts-turned-superhuman from exposure to cosmic rays during a space mission. The family is made up of Reed Richards (Pedro Pascal), who can stretch his body to incredible lengths; Sue Storm (Vanessa Kirby), who can render herself invisible; Johnny Storm (Joseph Quinn), who transforms into a fiery human torch; and Ben Grimm (Ebon Moss-Bachrach), who possesses tremendous superhuman strength with his stone-like flesh. The movie takes place four years after the family gained powers, during which Reed's inventions have transformed technology, and Sue's diplomacy has led to global peace. Both audiences and critics responded positively to the film, which currently has an 88% on Rotten Tomatoes and promising exit poll responses from opening weekend ticket buyers. An estimated 46% of audiences chose to see it on premium screens, including IMAX and other large formats. The once towering Marvel is working to rebuild audience enthusiasm for its films and characters. Its two previous offerings this year did not reach the cosmic box office heights of 'Deadpool & Wolverine," which made over $1.3 billion, or those of the 'Avengers'-era. But critically, the films have been on an upswing since the poorly reviewed 'Captain America: Brave New World,' which ultimately grossed $415 million worldwide. ' Thunderbolts," which jumpstarted the summer movie season, was better received critically but financially is capping out at just over $382 million globally. Like Deadpool and Wolverine, the Fantastic Four characters had been under the banner of 20th Century Fox for years. The studio produced two critically loathed, but decently profitable attempts in the mid-2000s with future Captain America Chris Evans as the Human Torch. In 2015, it tried again (unsuccessfully) with Michael B. Jordan and Miles Teller. They got another chance after Disney's $71 billion acquisition of Fox's entertainment assets in 2019. Top 10 movies by domestic box office With final domestic figures being released Monday, this list factors in the estimated ticket sales for Friday through Sunday at U.S. and Canadian theaters, according to Comscore: 1. 'The Fantastic Four: First Steps,' $118 million. 2. 'Superman,' $24.9 million. 3. 'Jurassic World Rebirth,' $13 million. 4. 'F1: The Movie,' $6.2 million. 5. 'Smurfs,' $5.4 million. 6. 'I Know What You Did Last Summer,' $5.1 million. 7. 'How to Train Your Dragon,' $2.8 million. 8. 'Eddington,' $1.7 million. 9. 'Saiyaara,' $1.3 million. 10. 'Oh, Hi!,' $1.1 million.


The Independent
2 hours ago
- The Independent
This fuzzy animal friend may be the key to treating schizophrenia
Llamas – likely without red pajamas – may hold the key to treating schizophrenia. The serious brain disorder causes people to interpret reality abnormally, and affects approximately 3.7 million U.S. adults between the ages of 18 to 65 years old, according to the nonprofit RTI International. But the domesticated South American woolly animal might be be able to help. French researchers said this week that they had used llama antibodies, or proteins that help to protect the immune system, to design a tiny fragment of an antibody known as a 'nanobody' that will trigger a neurotransmitter in the brain involved in regulating neural activity. Neurotransmitters are chemical molecules that carry messages or signals from one nerve cell to the next target cell, according to the Cleveland Clinic. No llamas were harmed in the study and researchers can identify nanobodies in a petri dish. In the past, llama antibodies have also proven effective in fighting Covid and other 'SARS-like' viruses. When scientists at the Institute of Functional Genomics injected the molecule into the veins or the muscles, it was able to break the blood-brain barrier and effectively reach brain receptors. The barrier is a a tightly locked layer of cells that defend your brain from harmful substances. Studying the impact of the nanobodies in two tests using mice, the researchers found that they corrected cognitive deficits that were observed. There was an improvement of cognitive function with just one shot, and a prolonged effect over one week. Clinical studies are now required to show that their findings could be a new avenue of treatment for schizophrenia. "In humans obviously we don't know [yet], but in mice yes, it is sufficient to treat most deficits of schizophrenia," molecular biologist Jean-Philippe Pin told Newsweek.. He was a co-author of the research which was published in the journal Nature. Pin said that medications currently given to schizophrenia patients "treat the symptoms well, but less the cognitive deficits." The cause of the chronic condition remains unknown, but the World Health Organization says it is thought that an interaction between genes and a range of environmental factors may be the reason. The exact prevalence of schizophrenia is difficult to measure. Some have tied cases in Canada to cannabis use. Although schizophrenia can occur at any age, people are typically diagnosed between the ages of 16 and 30. Symptoms vary from person to person. There is no cure, but it can be treated through antipsychotic medications, talk therapy, and self-management strategies, the National Alliance on Mental Illness says. The study's authors hope to add this strategy to the list. 'This research confirms the potential of nanobodies as a new therapeutic strategy for acting on the brain, with their use eventually being broadened to include the treatment of other neurological illnesses,' the institute said in a statement.